xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	rate of pathological complete response in primary tumor - in axillary lymph node (LN)-positive early-stage breast cancer	1221	1418	Treatment with XEC led to an increased rate of pathological complete response in primary tumor (18% vs 6%, respectively, P=0.027) and objective remission rate (87% vs 73%, P=0.048) compared to FEC.
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	hand-foot syndrome - in axillary lymph node (LN)-positive early-stage breast cancer	1500	1586	Compared to FEC, XEC was associated with more hand-foot syndrome (57% vs 11%, P<0.001)
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	3/4 grade nausea/vomiting/diarrhea - in axillary lymph node (LN)-positive early-stage breast cancer	1500	1647	Compared to FEC, XEC was associated with more hand-foot syndrome (57% vs 11%, P<0.001) and 3/4 grade nausea/vomiting/diarrhea (30% vs 14%, P=0.034)
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	objective remission rate - in axillary lymph node (LN)-positive early-stage breast cancer	1221	1417	Treatment with XEC led to an increased rate of pathological complete response in primary tumor (18% vs 6%, respectively, P=0.027) and objective remission rate (87% vs 73%, P=0.048) compared to FEC
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	clinical complete response (cCR) - in axillary lymph node (LN)-positive early-stage breast cancer	11941	12038	Treatment with XEC led to an increased rate of pCR (18% vs 6%, P=0.027), cCR (20% vs 7%, P=0.033)
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	objective remission rate - in axillary lymph node (LN)-positive early-stage breast cancer	1221	1418	Treatment with XEC led to an increased rate of pathological complete response in primary tumor (18% vs 6%, respectively, P=0.027) and objective remission rate (87% vs 73%, P=0.048) compared to FEC.
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	3/4 grade nausea/vomiting/diarrhea - in axillary lymph node (LN)-positive early-stage breast cancer	1500	1688	Compared to FEC, XEC was associated with more hand-foot syndrome (57% vs 11%, P<0.001) and 3/4 grade nausea/vomiting/diarrhea (30% vs 14%, P=0.034) but less phlebitis (3% vs 14%, P=0.035).
xeloda/ epirubicin/ cyclophosphamide (XEC)	5-fluorouracil/ epirubicin/ cyclophosphamide (FEC)	rate of pathological complete response in primary tumor - in axillary lymph node (LN)-positive early-stage breast cancer	1221	1350	Treatment with XEC led to an increased rate of pathological complete response in primary tumor (18% vs 6%, respectively, P=0.027)
